These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38745575)

  • 1. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights.
    Rubio T
    Hosp Pharm; 2016 Mar; 51(3):268. PubMed ID: 38745575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights.
    Rose B
    Hosp Pharm; 2016 Jun; 51(6):491-2. PubMed ID: 27354752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights.
    Klafehn CW
    Hosp Pharm; 2016 Sep; 51(8):688-691. PubMed ID: 27698510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights October - December 2016.
    Rose BJ
    Hosp Pharm; 2017 Feb; 52(2):153-154. PubMed ID: 28321144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights July-September 2016.
    Rubio T
    Hosp Pharm; 2016 Dec; 51(11):941-943. PubMed ID: 28057955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
    Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
    Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
    Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
    Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
    Yeh JS; Sarpatwari A; Kesselheim AS
    Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Summaries of safety labeling changes approved by FDA-Boxed Warnings Highlights October-December 2014.
    Rubio T
    Am J Health Syst Pharm; 2015 Mar; 72(5):343. PubMed ID: 25694404
    [No Abstract]   [Full Text] [Related]  

  • 11. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2019.
    Am J Health Syst Pharm; 2020 Apr; 77(8):e6-e8. PubMed ID: 32236460
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA boxed warnings: how to prescribe drugs safely.
    O'Connor NR
    Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights October-December 2015.
    Office of Health & Constituent Affairs U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2016 Mar; 73(5):267. PubMed ID: 26896495
    [No Abstract]   [Full Text] [Related]  

  • 14. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
    Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summaries of safety labeling changes approved by FDA-boxed warnings highlights, October-December 2023.
    Am J Health Syst Pharm; 2024 Apr; 81(9):e198-e205. PubMed ID: 38490964
    [No Abstract]   [Full Text] [Related]  

  • 16. Summaries of Safety Labeling Changes Approved By FDA-Boxed Warnings Highlights, October-December 2022.
    Am J Health Syst Pharm; 2023 Mar; 80(6):330. PubMed ID: 36806497
    [No Abstract]   [Full Text] [Related]  

  • 17. Summaries of Safety Labeling Changes Approved By FDA-Boxed Warnings Highlights, October-December 2022.
    Am J Health Syst Pharm; 2023 Mar; 80(6):e74-e75. PubMed ID: 36801981
    [No Abstract]   [Full Text] [Related]  

  • 18. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
    Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
    Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
    Mostaghim SR; Gagne JJ; Kesselheim AS
    BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
    [No Abstract]   [Full Text] [Related]  

  • 20. Summaries of safety labeling changes approved by FDA-boxed warnings highlights January-March 2016.
    Am J Health Syst Pharm; 2016 Jun; 73(11):e375-7. PubMed ID: 27208062
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.